Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Noel Barrett

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
The Journal of Infectious Diseases|November 18, 2011
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodiesRichard Fritz, Nicolas Sabarth, Stefan Kiermayr, et al.
Vaccine|December 17, 2011
Clinical development of a Vero cell culture-derived seasonal influenza vaccineHartmut J Ehrlich, Gregory Berezuk, Sandor Fritsch, et al.
Transfusion|July 14, 2006
Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivativesThomas R Kreil, Andreas Wieser, Andreas Berting, et al.
Vaccine|October 11, 2005
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responsesMartin Spruth, Otfried Kistner, Helga Savidis-Dacho, et al.
Vaccine|July 4, 2012
A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccinationNicolas Sabarth, Helga Savidis-Dacho, Michael G Schwendinger, et al.
Vaccine|November 15, 2003
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicityHartmut J Ehrlich, Borislava G Pavlova, Sandor Fritsch, et al.
Clinical and Vaccine Immunology : CVI|October 31, 2014
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adultsGerald Aichinger, Barbara Grohmann-Izay, Maikel V W van der Velden, et al.
Plos One|February 14, 2014
MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesAnnett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, et al.
Open Forum Infectious Diseases|March 4, 2015
Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised PatientsRichard Fritz, Nicole Hetzelt, Reinhard Ilk, et al.
The Journal of Infectious Diseases|May 20, 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humansKlaus K Orlinger, Yvonne Hofmeister, Richard Fritz, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
The Journal of Infectious Diseases|November 18, 2011
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodiesRichard Fritz, Nicolas Sabarth, Stefan Kiermayr, et al.
Vaccine|December 17, 2011
Clinical development of a Vero cell culture-derived seasonal influenza vaccineHartmut J Ehrlich, Gregory Berezuk, Sandor Fritsch, et al.
Transfusion|July 14, 2006
Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivativesThomas R Kreil, Andreas Wieser, Andreas Berting, et al.
Vaccine|October 11, 2005
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responsesMartin Spruth, Otfried Kistner, Helga Savidis-Dacho, et al.
Vaccine|July 4, 2012
A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccinationNicolas Sabarth, Helga Savidis-Dacho, Michael G Schwendinger, et al.
Vaccine|November 15, 2003
Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicityHartmut J Ehrlich, Borislava G Pavlova, Sandor Fritsch, et al.
Clinical and Vaccine Immunology : CVI|October 31, 2014
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adultsGerald Aichinger, Barbara Grohmann-Izay, Maikel V W van der Velden, et al.
Plos One|February 14, 2014
MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesAnnett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, et al.
Open Forum Infectious Diseases|March 4, 2015
Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised PatientsRichard Fritz, Nicole Hetzelt, Reinhard Ilk, et al.
The Journal of Infectious Diseases|May 20, 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humansKlaus K Orlinger, Yvonne Hofmeister, Richard Fritz, et al.
Pageof 7